CANNAPHARMARX, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.4M | $820.1K | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | $3.4M | $3.8M | $0 | — | — | — | — |
| Gross Profit | — | $-2.1M | $-2.9M | $0 | — | — | — | — |
| Gross Margin | — | -153.1% | -357.9% | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | — | $489.6K | $116.6K | $703.6K | $2.2M | $852.6K | $2.1M | $477.9K |
| Operating Income | — | $-3.3M | $-3.6M | $-1.6M | $-5.2M | $-3.0M | $-14.5M | $-16.0M |
| Operating Margin | — | -245.8% | -442.7% | — | — | — | — | — |
| Interest Expense | — | $2.0M | $2.3M | $1.7M | $2.3M | $1.5M | $2.3M | $4.5M |
| Pretax Income | — | — | — | — | $-8.5M | $-8.8M | $-19.9M | $-20.5M |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-11.1M | $-9.9M | $3.7M | $-8.5M | $-8.8M | $-19.9M | $-20.5M |
| Net Margin | — | -817.2% | -1,207.8% | — | — | — | — | — |
| EPS (Basic) | — | — | — | — | $0.02 | $0.02 | $-0.08 | $-0.11 |
| EPS (Diluted) | — | $-0.02 | $-0.02 | $0.01 | $0.02 | $0.02 | $-0.08 | $-0.11 |
| Shares Outstanding (Basic) | 678.5M | — | — | — | 422.1M | 448.1M | 244.2M | — |
| Shares Outstanding (Diluted) | 678.5M | 662.5M | 625.3M | 617.9M | 422.1M | 448.1M | 244.2M | 187.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |